Literature DB >> 21309615

Sample size and power for cost-effectiveness analysis (part 1).

Henry A Glick1.   

Abstract

Basic sample size and power formulae for cost-effectiveness analysis have been established in the literature. These formulae are reviewed and the similarities and differences between sample size and power for cost-effectiveness analysis and for the analysis of other continuous variables such as changes in blood pressure or weight are described. The types of sample size and power tables that are commonly calculated for cost-effectiveness analysis are also described and the impact of varying the assumed parameter values on the resulting sample size and power estimates is discussed. Finally, the way in which the data for these calculations may be derived are discussed.

Mesh:

Year:  2011        PMID: 21309615     DOI: 10.2165/11585070-000000000-00000

Source DB:  PubMed          Journal:  Pharmacoeconomics        ISSN: 1170-7690            Impact factor:   4.981


  18 in total

1.  Power and sample size in cost-effectiveness analysis.

Authors:  E M Laska; M Meisner; C Siegel
Journal:  Med Decis Making       Date:  1999 Jul-Sep       Impact factor: 2.583

Review 2.  Parameter solicitation for planning cost effectiveness studies with dichotomous outcomes.

Authors:  M McIntosh; S Ramsey; K Berry; N Urban
Journal:  Health Econ       Date:  2001-01       Impact factor: 3.046

3.  Analysis, sample size, and power for estimating incremental net health benefit from clinical trial data.

Authors:  A R Willan
Journal:  Control Clin Trials       Date:  2001-06

4.  Sample size and power issues in estimating incremental cost-effectiveness ratios from clinical trials data.

Authors:  A R Willan; B J O'Brien
Journal:  Health Econ       Date:  1999-05       Impact factor: 3.046

5.  Use of cost-effectiveness analysis in health-care resource allocation decision-making: how are cost-effectiveness thresholds expected to emerge?

Authors:  Hans-Georg Eichler; Sheldon X Kong; William C Gerth; Panagiotis Mavros; Bengt Jönsson
Journal:  Value Health       Date:  2004 Sep-Oct       Impact factor: 5.725

6.  Sample size calculation in economic evaluations.

Authors:  M J Al; B A van Hout; B C Michel; F F Rutten
Journal:  Health Econ       Date:  1998-06       Impact factor: 3.046

7.  Sample size and power for cost-effectiveness analysis (Part 2): the effect of maximum willingness to pay.

Authors:  Henry A Glick
Journal:  Pharmacoeconomics       Date:  2011-04       Impact factor: 4.981

8.  Confidence intervals for cost-effectiveness ratios: a comparison of four methods.

Authors:  D Polsky; H A Glick; R Willke; K Schulman
Journal:  Health Econ       Date:  1997 May-Jun       Impact factor: 3.046

9.  Bevacizumab in combination with paclitaxel for HER-2 negative metastatic breast cancer: an economic evaluation.

Authors:  Konstantin J Dedes; Klazien Matter-Walstra; Matthias Schwenkglenks; Bernhard C Pestalozzi; Daniel Fink; Peter Brauchli; Thomas D Szucs
Journal:  Eur J Cancer       Date:  2009-01-13       Impact factor: 9.162

10.  Value of information analyses of economic randomized controlled trials: the treatment of intermittent claudication.

Authors:  Bas Groot Koerkamp; Sandra Spronk; Theo Stijnen; M G Myriam Hunink
Journal:  Value Health       Date:  2009-10-08       Impact factor: 5.725

View more
  22 in total

1.  Output correlations in probabilistic models with multiple alternatives.

Authors:  Klemen Naveršnik
Journal:  Eur J Health Econ       Date:  2014-01-04

2.  Is a diabetes pay-for-performance program cost-effective under the National Health Insurance in Taiwan?

Authors:  Elise Chia-Hui Tan; Raoh-Fang Pwu; Duan-Rung Chen; Ming-Chin Yang
Journal:  Qual Life Res       Date:  2013-08-23       Impact factor: 4.147

Review 3.  Cost-effectiveness of collaborative care for the treatment of depressive disorders in primary care: a systematic review.

Authors:  Thomas Grochtdreis; Christian Brettschneider; Annemarie Wegener; Birgit Watzke; Steffi Riedel-Heller; Martin Härter; Hans-Helmut König
Journal:  PLoS One       Date:  2015-05-19       Impact factor: 3.240

4.  A culturally adapted lifestyle intervention addressing a Middle Eastern immigrant population at risk of diabetes, the MEDIM (impact of Migration and Ethnicity on Diabetes In Malmö): study protocol for a randomized controlled trial.

Authors:  Sanjib Saha; Matti Leijon; Ulf Gerdtham; Kristina Sundquist; Jan Sundquist; Daniel Arvidsson; Louise Bennet
Journal:  Trials       Date:  2013-09-03       Impact factor: 2.279

5.  Protocol for the economic evaluation of the diarrhea alleviation through zinc and oral rehydration salt therapy at scale through private and public providers in rural Gujarat and Uttar Pradesh, India.

Authors:  Samuel D Shillcutt; Amnesty E LeFevre; Christa L Fischer Walker; Robert E Black; Sarmila Mazumder
Journal:  Implement Sci       Date:  2014-11-19       Impact factor: 7.327

6.  Cost-effectiveness analysis of the diarrhea alleviation through zinc and oral rehydration therapy (DAZT) program in rural Gujarat India: an application of the net-benefit regression framework.

Authors:  Samuel D Shillcutt; Amnesty E LeFevre; Christa L Fischer-Walker; Sunita Taneja; Robert E Black; Sarmila Mazumder
Journal:  Cost Eff Resour Alloc       Date:  2017-06-08

7.  Randomised, prospective, medico-economic nationwide French study of islet transplantation in patients with severely unstable type 1 diabetes: the STABILOT study protocol.

Authors:  Sandrine Lablanche; Sandra David-Tchouda; Jennifer Margier; Edith Schir; Anne Wojtusciszyn; Sophie Borot; Laurence Kessler; Emmanuel Morelon; Charles Thivolet; François Pattou; Marie Christine Vantyghem; Thierry Berney; Pierre-Yves Benhamou
Journal:  BMJ Open       Date:  2017-02-20       Impact factor: 2.692

8.  Cost-benefit and extended cost-effectiveness analysis of a comprehensive adolescent pregnancy prevention program in Zambia: study protocol for a cluster randomized controlled trial.

Authors:  Amani Thomas Mori; Linda Kampata; Patrick Musonda; Kjell Arne Johansson; Bjarne Robberstad; Ingvild Sandøy
Journal:  Trials       Date:  2017-12-19       Impact factor: 2.279

9.  Cost-effectiveness of blended vs. face-to-face cognitive behavioural therapy for severe anxiety disorders: study protocol of a randomized controlled trial.

Authors:  Geke Romijn; Heleen Riper; Robin Kok; Tara Donker; Maartje Goorden; Leona Hakkaart van Roijen; Lisa Kooistra; Anton van Balkom; Jeroen Koning
Journal:  BMC Psychiatry       Date:  2015-12-12       Impact factor: 3.630

10.  Choosing the target difference and undertaking and reporting the sample size calculation for a randomised controlled trial - the development of the DELTA2 guidance.

Authors:  William Sones; Steven A Julious; Joanne C Rothwell; Craig Robert Ramsay; Lisa V Hampson; Richard Emsley; Stephen J Walters; Catherine Hewitt; Martin Bland; Dean A Fergusson; Jesse A Berlin; Doug Altman; Luke David Vale; Jonathan Alistair Cook
Journal:  Trials       Date:  2018-10-10       Impact factor: 2.279

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.